M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen
Chinese biotechnology company Guanhao Biotech plans to acquire a 53.4% stake in two pharmaceutical companies based in China for CNY266m ($39.95m).
US-based pharmaceutical company Cancer Genetics Inc (CGI) plans to acquire Australian preclinical oncology services provider vivoPharm for $12m. The acquisition is expected to strengthen CGI’s business.
South Korean pharmaceutical company Alvogen plans to acquire Russian pharmaceutical firm Omega Bittner from Irish healthcare company Perrigo Company.
The acquisition will strengthen Alvogen’s business in Russia.